The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Does the Metabolic Syndrome Improve Identification of Individuals at Risk of Type 2 Diabetes and/or Cardiovascular Disease?
Abstract
OBJECTIVE—The metabolic syndrome has been promoted as a method for identifying high-risk individuals for type 2 diabetes and cardiovascular disease (CVD). We therefore sought to compare this syndrome, as defined by the National Cholesterol Education Program, to the Diabetes Predicting Model and the Framingham Risk Score as predictors of type 2 diabetes and CVD, respectively. RESEARCH DESIGN AND METHODS—A population-based sample of 1,709 initially nondiabetic San Antonio Heart Study (SAHS) participants were followed for 7.5 years, 195 of whom developed type 2 diabetes. Over the same time interval, 156 of 2,570 SAHS participants experienced a cardiovascular event. A population-based sample of 1,353 initially nondiabetic Mexico City Diabetes Study (MCDS) participants were followed for 6.5 years, 125 of whom developed type 2 diabetes. Baseline measurements included medical history, age, sex, ethnicity, smoking status, BMI, blood pressure, fasting and 2-h plasma glucose levels, and fasting serum total and HDL cholesterol and triglycerides. RESULTS—The sensitivities for predicting diabetes with the metabolic syndrome were 66.2 and 62.4% in the SAHS and the MCDS, respectively, and the false-positive rates were 27.8 and 38.7%, respectively. The sensitivity and false-positive rates for predicting CVD with the metabolic syndrome in the SAHS were 67.3 and 34.2%, respectively. At corresponding false-positive rates, the two predicting models had significantly higher sensitivities and, at corresponding sensitivities, significantly lower false-positive rates than the metabolic syndrome for both end points. Combining the metabolic syndrome with either predicting model did not improve the prediction of either end point. CONCLUSIONS—The metabolic syndrome is inferior to established predicting models for either type 2 diabetes or CVD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with the metabolic syndrome also are at increased risk for developing type 2 diabetes mellitus.”
From Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (2005) · cites this paper as [61]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
Pepe, M. S. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh101 · Cited by 1,276
Laaksonen, D. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf145 · Cited by 916
Edelstein, S. L., Knowler, W. C., Bain, R. P., Andres, R., Barrett-Connor, E. L., Dowse, G. K., Haffher, S. M., Pettitt, D. J., Sorkin, J. D., Muller, D. C., et al. (1997) · Diabetes · doi:10.2337/diab.46.4.701 · Cited by 641
Cited by
Sorted by citations
Items 701–733 of 733
Schipf, S., Markus, M. R. P., & Dörr, M. (2019) · Springer Reference Pflege, Therapie, Gesundheit · doi:10.1007/978-3-662-55793-8_54-1
Garg, R. (2014) · doi:10.1093/med/9780199358274.003.0053
Obesity, Metabolic Syndrome and Type 2 Diabetes
Steinberger, J., Kelly, A. S., & Ryder, J. R. (2021) · Springer eBooks · doi:10.1007/978-1-4471-4999-6_53-2
To evaluate the safety and efficacy of saroglitazar among pre-diabetes and dyslipidemia
Dhone, P. G., Behera, D., Gupta, V. K., & Mubeen, M. F. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns2.8835
Mechanisms of Action of Berry Bioactives on Obesity-induced Inflammation
Giampieri, F., Cianciosi, D., Ansary, J., Forbes-Hernández, T. Y., Álvarez-Suárez, J. M., & Battino, M. A. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839165450-00335
da Silva, D. A. R., de Almeida, L. S., Correa, L. L., Pimentel, R., Gomes, A. T., Travassos, A. G., Viana, A. M., Cerqueira, M. M. B. D. F., de Souza, M. C., de Sousa, A. D., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191610203 · Cited by 1
Metabolisk syndrom, diabetes mellitus og disse tilstandes betydning for mundhulen
Grauballe, M. B., Rydnert, J. A. G., Clausen, L. G., Holmstrup, P., Flyvbjerg, A., & Schou, S. (2012) · Den norske tannlegeforenings Tidende · doi:10.56373/2012-1-20
Rasul, D. A., & Al-Othman, A. (2015) · Advanced medical journal · doi:10.56056/amj.2015.06
Prevalence of metabolic syndrome in female patients with rheumatoid arthritis in Erbil city
Othman, M. A., & Meena, M. Q. (2023) · Diyala Journal of Medicine · doi:10.26505/djm.v24i1.967
Chowdhury, M. T. (2022) · Current Research in Diabetes & Obesity Journal · doi:10.19080/crdoj.2022.15.555915
Zhu, J., Qin, C., He, Q., Zhou, B., Xia, Y., & Tan, X. (2023) · doi:10.2196/preprints.48779
Saeed, M. A., Akhtar, M., Munir, M. A., Ayub, K., Nazir, T., Arshad, M., & Samad, H. (2023) · JAIMC Journal of Allama Iqbal Medical College · doi:10.59058/jaimc.v21i1.102
Rampazzo, J. A., Romeiro, E. T., Perez, H. B. P., dos Santos, L. B. D., de Lima, A., Vargas, C. V., Barcelar, M. G. P., Rigaud, J. B., Dias, P. C., & de Andrade, M. P. (2024) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v10i1.13102
METABOLIC SYNDROME RELATIONSHIP AND RISK FACTORS ASSOCIATED WITH IMMEDIATE LIFE PATH ENVIRONMENTS
Jefferson, J. (2024) · Health and Society · doi:10.51249/hs.v4i02.1966
Dentali, F., & Rotunno, S. (2024) · Italian Journal of Medicine · doi:10.4081/itjm.q.2024.4
Zhu, M., & Pan, F. (2024) · Research Square · doi:10.21203/rs.3.rs-4676728/v1
Multidimensional role of melatonin
Olajide, P. A., Adetuyi, B. O., Oni, P. G., Oyebanjo, O. T., Ambali, O. A., & Ogunlana, O. O. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13814-0.00008-9
Parul, S. S., Ahmmed, R., Hasan, M. M.-U., Islam, A., Rahman, M. M., Manirujjaman, M., Bari, M. W., Ahmed, M. U., Hasan, M. M.-U., & Islam, M. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.15.618480
Thauerer, B., Odrovicsné-Tóth, A., Salzer, A., & Steinecker-Frohnwieser, B. (2024) · Biomolecules · doi:10.3390/biom14121527
Phytotherapy Products and Active Principles
Romano, C. A., de Paula, J. R., Elusiyan, C. A., & Fajemiroye, J. O. (2025) · Springer eBooks · doi:10.1007/978-3-031-80107-5_5
Soto, E. A. M., López, P. E. E., Andrade, H. D. Z., Garcia, M. A. R., & Mascareño, C. G. C. (2025) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v9i2.17520
The Metabolic Syndrome: Definitions, Controversies and Clinical Utility
Johnson, L. W., & Weinstock, R. S. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-192-5_1
Marković, M., Gotić, J., & Radovanović, J. (2025) · Timocki medicinski glasnik · doi:10.5937/tmg2503082m
Paulo, L. S., Piedade, G. J., Mayala, S., Harris, V., Lenters, V. C., Mende, D. R., Kamuhabwa, A. A. R., Kwesigabo, G., Asselbergs, F. W., Chillo, P., et al. (2026) · BMC Public Health · doi:10.1186/s12889-025-25653-1
Impact de la protéine SHP2 associé au syndrome de Noonan sur le métabolisme glucidique
Paccoud, R. (2018) · theses.fr (ABES) · doi:10.70675/f9b9b046zdf4bz404fz9689z8deb20f6e5ac
Harper, L. A. (2014) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/jxe0-3s77
Neeb, Z. P. (2010) · IUScholarWorks (Indiana University) · doi:10.7912/c2/1992
Metadata
- Authors
- Stern, M. P., Williams, K., González-Villalpando, C., Hunt, K. J., & Haffner, S. M.
- Affiliations
- Division of Clinical Epidemiology, Department of Medicine, University of Texas Health Science Center, San Antonio, Texas
- The University of Texas at San Antonio Health Science Center (US)
- Centro de Estudios en Diabetes, The American British Cowdray Hospital and Unidades de Investigación Médica en Enfermedades Metabólicas y Epidemiología Clínica, Hospital Gabriel Mancera, Instituto Mexicano del Seguro Social, Mexico City, Mexico
- ORCID
- Hunt, Kelly J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2004-11-01
- Volume
- 27
- Issue
- 11
- Pages
- 2676-2681
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1975366890
- Cited by
- 735
- References
- 17
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 19 · 2023: 15 · 2022: 19 · 2021: 21 · 2020: 13 · 2019: 24 · 2018: 29 · 2017: 33 · 2016: 35 · 2015: 48 · 2014: 39 · 2013: 40 · 2012: 43
- FWCI
- 31.54
- Type
- journal article
- Language
- en
- Update notices
- correction (2005-01-01)
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL024799, R01HL036820)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Keywords
- metabolic syndrome, type 2 diabetes, cardiovascular disease, risk prediction, Framingham risk score, sensitivity and false positive rate, San Antonio Heart Study, risk stratification
- MeSH terms
- Adult, Cardiovascular Diseases, Diabetes Mellitus, Type 2, False Positive Reactions, Female, Humans, Male, Middle Aged, Models, Biological, Predictive Value of Tests, Risk, Likelihood Functions, Metabolic Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
